Carvolix Company Description

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France.

It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm.

The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026.

Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.

Carvolix SA

Country	France
Founded	2011
Industry	Medical Devices
Sector	Healthcare
Employees	68
CEO	Sebastien Ladet

Contact Details

Address: 320, avenue ArchimEde Aix-en-Provence, 13100 France
Phone	33 4 42 95 12 20
Website	carvolix.eu

Stock Details

Ticker Symbol	CVX
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0013333077
SIC Code	3842

Key Executives

Name	Position
Olivier Pierron	Deputy Chief Executive Officer
Sebastien Ladet Ph.D.	Chief Executive Officer
Christophe de Vregille	Chief Financial Officer
Celine Buard	Head of marketing and EU Commercialization
Melanie Cantal	Human Resources Manager
Nicolas Barry Delongchamps M.D.	Chief Medical Officer and Member of Scientific Advisory Board
Prof. Francois Laborde M.D., Ph.D.	Chief Surgical Officer
Benjamin Renault Ph.D.	Chief Development Officer
Dr. Howard C. Herrmann M.D.	Chief Medical Officer
Pierre Berthet-Rayne Ph.D.	Chief Technology Officer Robotics